



Novel approaches in triple-negative and HR+/HER2– metastatic breast cancer

Gilead Symposium

Monday, 12 September 2022, 13:00–14:30 (CEST)

7.2.F – Fécamp Auditorium, Hall 7, Level 7.2, Paris Expo Porte de Versailles, Paris, France

13:00–13:05



Welcome and introduction

Prof. Martine Piccart
(Chair)

Scientific Director,
Institut Jules Bordet,
Brussels, Belgium

13:05–13:20



Stepping into the
emerging needs
in metastatic
breast cancer

Dr. Marleen Kok

Group Leader, Netherlands
Cancer Institute, Amsterdam,
Netherlands

13:20–13:40



Exploring current
treatment
approaches for
triple-negative
and HR+/HER2–
metastatic breast
cancer

Dr. Véronique Diéras

Medical Oncologist and
Head, Breast Cancer Group
Department of Medical
Oncology, Centre Eugène
Marquis, Rennes, France

13:40–14:05



Expanding
possibilities in
triple-negative
and HR+/HER2–
metastatic breast
cancer

Prof. Peter Schmid

Professor of Cancer
Medicine and Lead, Centre
of Experimental Cancer
Medicine, Barts Cancer
Institute, London, United
Kingdom

14:05–14:25

Audience Q&A

All faculty

14:25–14:30

Closing remarks

Prof. Martine Piccart